Sol-Gel Technologies (SLGL) Share-based Compensation (2017 - 2025)
Sol-Gel Technologies' (SLGL) quarterly Share-based Compensation came in at $100000.0 in Q2 2025, down 63.64% year-on-year from $275000.0 in Q2 2024, and down 63.64% on a QoQ basis from $275000.0 in Q2 2024.
Sol-Gel Technologies (SLGL) Share-based Compensation (2017 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has 8 years of Share-based Compensation data on file, last reported at $100000.0 in Q2 2025.
- On a quarterly basis, Share-based Compensation fell 63.64% year-over-year to $100000.0 in Q2 2025; TTM through Jun 2025 was $1.2 million, a 8.45% decrease from a year earlier, with the FY2025 full-year figure at $82000.0, down 89.57% from the prior year.
- Share-based Compensation for Q2 2025 stood at $100000.0, down from $275000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for SLGL reached as high as $498000.0 in Q2 2023 and fell as low as $100000.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $287600.0 across 5 years, with a median of $275000.0 in 2024.
- Across the five-year window, Share-based Compensation soared 65.26% in 2022 and plunged 63.64% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $213000.0 in 2021, then jumped by 65.26% to $352000.0 in 2022, then jumped by 41.48% to $498000.0 in 2023, then slumped by 44.78% to $275000.0 in 2024, then plunged by 63.64% to $100000.0 in 2025.
- Per Business Quant data, the three most recent Share-based Compensation figures were $100000.0 in Q2 2025, $275000.0 in Q2 2024, and $498000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | Sol-Gel Technologies | 234.04 Mn | 223.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2023 | 498,000.00 |
| Jun 30, 2023 | 498,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Jun 30, 2021 | 213,000.00 |
| Jun 30, 2021 | 213,000.00 |
| Jun 30, 2020 | 315,000.00 |
| Jun 30, 2020 | 315,000.00 |
| Dec 31, 2018 | 2.93 Mn |
| Dec 31, 2018 | 2.93 Mn |
| Dec 31, 2017 | 1.80 Mn |
| Dec 31, 2017 | 1.80 Mn |